AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

NCT00890825 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: AZD6244
DRUG: docetaxel
DRUG: Placebo

Sponsor

AstraZeneca